FY27 Growth: Sustained momentum
Management expects to sustain the growth trajectory achieved in FY26 (38% YoY for 9 months) into FY27 as well, with stable margins in the 35-37% range.
SUDEEPPHRM / guidance tracker
Keep management guidance in view.
Sudeep Pharma · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
Battery Materials Phase-1 Commissioning: Q1 FY27
Deage battery materials facility (25,000 MT phase-1 capacity) remains on track for commissioning in early 2027, with total project capex of ₹300 crore for phase-1 out of ₹550-600 crore for full 100,000 MT.
Nandiseri Greenfield: March 2026 Commissioning
The 51,200 MT facility for gluconates, glycinates, and citrates will commission next month (March 2026); ramp-up expected in H2 FY26 with meaningful contribution in FY28, targeting 30-40% utilization.
Specialty Ingredients Utilization: 70-80% in 2 Years
Currently at 35-40% utilization with recent approvals from leading infant nutrition and bakery companies; management targets optimal utilization levels within the next two years.